Saturday, November 26, 2022
wellness India Expo


Dr Krishna Ella bestowed with AVRA Technology Award 2021

Dr Ella while delivering the award lecture, said there was a requirement to create an ecosystem where India should innovate and not copy from other countries and encourage start-ups

USFDA declines EUA nod to Covaxin

Despite receiving emergency use listing from the World Health Organization, Covaxin has not been cleared for any age group in the United States

Bharat Biotech gets DCGI nod for Phase 3 clinical trials of...

The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.

COVAXIN (BBV152) booster shown to neutralize both Omicron & Delta variants...

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

COVAXIN booster dose study shows promising results

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

First-ever study in India claims Covid-19 vaccine cocktails are safe

Mix and match of different vaccines is safe and elicits robust antibody response, revealed the study conducted by AIG Hospitals The first pilot study from India analyzing COVAXIN – COVISHEILD mixed doses

COVAXIN for children: Study demonstrates robust safety & immunogenicity in 2-18...

Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults......................

Covaxin P3 data published in Lancet, overall 77.8% efficacy confirmed

This first publication of the data shows COVAXIN has 93.4% efficacy against severe COVID-19 disease, 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of 25,798 participants..........................

Bharat Biotech’s partner seeks Covaxin nod in US for children between...

Covaxin, developed in India by Bharat Biotech, gained emergency approval from the World Health Organization (WHO) and has already been cleared for use in 17 countries......................

Covaxin gets nod for kids aged 2-18 years

The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group